SBFM vs. BRK-B
SBFM (Sunshine Biopharma Inc) and BRK-B (Berkshire Hathaway Inc.) are both stocks. SBFM operates in Drug Manufacturers - Specialty & Generic (Healthcare), while BRK-B operates in Insurance - Diversified (Financial Services). Over the past 10 years, SBFM returned -51.26%/yr vs 13.06%/yr for BRK-B. At a 0.02 correlation, their price movements are largely independent.
Performance
SBFM vs. BRK-B - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SBFM achieves a -83.01% return, which is significantly lower than BRK-B's -1.78% return. Over the past 10 years, SBFM has underperformed BRK-B with an annualized return of -51.26%, while BRK-B has yielded a comparatively higher 13.06% annualized return.
SBFM
- 1D
- -2.34%
- 1M
- -5.86%
- 6M
- -84.29%
- YTD
- -83.01%
- 1Y
- -86.43%
- 3Y*
- -94.06%
- 5Y*
- -76.38%
- 10Y*
- -51.26%
BRK-B
- 1D
- -0.35%
- 1M
- 0.91%
- 6M
- -1.08%
- YTD
- -1.78%
- 1Y
- 3.75%
- 3Y*
- 12.87%
- 5Y*
- 11.97%
- 10Y*
- 13.06%
SBFM vs. BRK-B - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SBFM Sunshine Biopharma Inc | -83.01% | -59.00% | -99.45% | -57.58% | 994.95% | 272.29% | 3,388.89% | -97.19% | -93.28% | 197.50% |
BRK-B Berkshire Hathaway Inc. | -1.78% | 10.89% | 27.09% | 15.46% | 3.31% | 28.95% | 2.37% | 10.93% | 3.01% | 21.62% |
Correlation
The correlation between SBFM and BRK-B is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.13 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.11 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.04 |
Correlation (All Time) Calculated using the full available price history since Oct 30, 2009 | 0.02 |
The correlation between SBFM and BRK-B shifts across timeframes, from 0.02 (all time) to 0.13 (3 years), reflecting how their relationship changes across market environments.
Fundamentals
SBFM:
$1.05M
BRK-B:
$1.06T
SBFM:
-$1.36
BRK-B:
$33.62
SBFM:
0.25
BRK-B:
2.84
SBFM:
0.38
BRK-B:
1.46
SBFM:
$36.31M
BRK-B:
$375.39B
SBFM:
$12.26M
BRK-B:
$94.36B
SBFM:
-$5.62M
BRK-B:
$71.92B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SBFM vs. BRK-B — Risk / Return Rank
SBFM
BRK-B
SBFM vs. BRK-B - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Sunshine Biopharma Inc (SBFM) and Berkshire Hathaway Inc. (BRK-B). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SBFM | BRK-B | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.90 | ||
| Sortino ratioReturn per unit of downside risk | -1.93 | ||
| Omega ratioGain probability vs. loss probability | 0.76 | 1.05 | -0.29 |
| Calmar ratioReturn relative to maximum drawdown | -0.96 | 0.34 | -1.30 |
| Martin ratioReturn relative to average drawdown | -1.82 | 0.73 | -2.55 |
Loading charts...
Drawdowns
SBFM vs. BRK-B - Drawdown Comparison
The maximum SBFM drawdown since its inception was -100.00%, which is greater than BRK-B's maximum drawdown of -53.86%. Use the drawdown chart below to compare losses from any high point for SBFM and BRK-B.
Loading charts...
Drawdown Indicators
| SBFM | BRK-B | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -53.86% | -46.14% |
Max Drawdown (1Y)Largest decline over 1 year | -90.73% | -9.42% | -81.31% |
Max Drawdown (3Y)Largest decline over 3 years | -99.98% | -14.95% | -85.03% |
Max Drawdown (5Y)Largest decline over 5 years | -100.00% | -26.58% | -73.42% |
Max Drawdown (10Y)Largest decline over 10 years | -100.00% | -29.57% | -70.43% |
Current DrawdownCurrent decline from peak | -100.00% | -8.54% | -91.46% |
Average DrawdownAverage peak-to-trough decline | -88.87% | -11.06% | -77.81% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 47.70% | 4.45% | +43.25% |
Volatility
SBFM vs. BRK-B - Volatility Comparison
Sunshine Biopharma Inc (SBFM) has a higher volatility of 19.21% compared to Berkshire Hathaway Inc. (BRK-B) at 4.46%. This indicates that SBFM's price experiences larger fluctuations and is considered to be riskier than BRK-B based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SBFM | BRK-B | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.21% | 4.46% | +14.75% |
Volatility (6M)Calculated over the trailing 6-month period | 117.34% | 10.98% | +106.36% |
Volatility (1Y)Calculated over the trailing 1-year period | 128.30% | 14.51% | +113.79% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 6,608.56% | 17.10% | +6,591.46% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 4,761.94% | 19.39% | +4,742.55% |
Dividends
SBFM vs. BRK-B - Dividend Comparison
Neither SBFM nor BRK-B has paid dividends to shareholders.
Financials
SBFM vs. BRK-B - Financials Comparison
This section allows you to compare key financial metrics between Sunshine Biopharma Inc and Berkshire Hathaway Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SBFM vs. BRK-B - Profitability Comparison
SBFM - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Sunshine Biopharma Inc reported a gross profit of 3.03M and revenue of 8.58M. Therefore, the gross margin over that period was 35.3%.
BRK-B - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Berkshire Hathaway Inc. reported a gross profit of 26.98B and revenue of 93.68B. Therefore, the gross margin over that period was 28.8%.
SBFM - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Sunshine Biopharma Inc reported an operating income of -1.79M and revenue of 8.58M, resulting in an operating margin of -20.9%.
BRK-B - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Berkshire Hathaway Inc. reported an operating income of 15.05B and revenue of 93.68B, resulting in an operating margin of 16.1%.
SBFM - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Sunshine Biopharma Inc reported a net income of -2.14M and revenue of 8.58M, resulting in a net margin of -25.0%.
BRK-B - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Berkshire Hathaway Inc. reported a net income of 10.18B and revenue of 93.68B, resulting in a net margin of 10.9%.
Frequently Asked Questions
SBFM and BRK-B have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SBFM has higher volatility (19.21%) compared to BRK-B (4.46%). In terms of maximum drawdown, SBFM dropped -100.00% vs BRK-B's -53.86%.
BRK-B currently has the higher Sharpe Ratio (0.22 vs -0.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SBFM and BRK-B
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer